Business Context and Reporting Period
This Form 8-K Current Report was filed by uniQure N.V. on August 7, 2017. The filing primarily addresses significant changes in corporate leadership, the appointment of new officers, and the scheduling of an Extraordinary General Meeting (EGM) of shareholders to elect new directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused on corporate governance and personnel changes rather than financial performance.
Material Changes and Personnel Appointments
- Scott McMillan: Appointed Chief Operating Officer (COO) effective August 7, 2017.
- Base Salary: $360,000 annually.
- Bonus: Up to 40% of base salary.
- Equity: Option to purchase 150,000 ordinary shares, vesting over four years (25% after 12 months, remainder quarterly).
- Severance: 100% of annual base salary upon termination without cause or for "Good Reason."
- Christian Klemt: Appointed Chief Accounting Officer (CAO) effective July 1, 2017.
- Base Salary: EUR 200,000 annually (includes 8% holiday allowance).
- Bonus: Up to 35% of annual gross salary.
- One-time Bonus: EUR 20,000 for past service.
- Severance: 100% of base pay upon termination by the company (excluding summary dismissal or culpable acts).
- Sander van Deventer: Transitioned from non-executive director to Chief Scientific Officer and General Manager, Amsterdam, effective August 7, 2017. He will resign from the Board upon the appointment of his successor at the upcoming EGM.
Corporate Governance and Outlook
Extraordinary General Meeting (EGM): The Company announced an EGM scheduled for September 14, 2017. Shareholders of record as of August 17, 2017, will be entitled to vote.
Board Nominations: The Board has nominated two new directors to be voted on at the EGM:
- Madhavan Balachandran: Former Executive Vice President of Operations at Amgen Inc. and current director of Catalent.
- Jeremy Springhorn, Ph.D.: Former Partner at Flagship Pioneering and former Vice President of Corporate Strategy at Alexion Pharmaceuticals.
Board Resignations: Will Lewis and Sander van Deventer are scheduled to resign from the Board of Directors upon the appointment of their successors at the EGM.
Investor Verification Checklist
- Verify the terms of the employment agreements for Scott McMillan and Christian Klemt in the upcoming 10-Q filing for the quarter ended June 30, 2017.
- Confirm the final composition of the Board of Directors following the September 14, 2017, EGM.
- Review the proxy statement for the EGM for detailed biographies and voting procedures.
- Monitor the transition of Sander van Deventer from the Board to the executive role and his subsequent resignation from Forbion Capital Partners by June 30, 2018.